Peniramin

Quick links to important sections

Peniramin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Peniramin

What is Peniramin: Identity and Classification

This section provides a clear, foundational understanding of the medicine Peniramin, detailing its composition, pharmacological class, and general purpose without discussing specific dosages or administration regimens.


Quick Facts

Property Description
Active Ingredient Chlorphenamine maleate
Form Tablet, Syrup, Injectable Solution
Pharmacological Class Antihistamine (H₁ Receptor Antagonist)
Common Use Relief from allergic reactions/hypersensitivity
Origin Synthetic (Propylamine Derivative)

What Type of Medicine is Peniramin?

Peniramin is a medication primarily known in certain jurisdictions and is categorized as a synthetic first-generation H₁ receptor antagonist, functioning as a systemic antihistamine. It belongs to the alkylamine chemical class, which is clinically recognized for its efficacy in blocking the effects of histamine.

As a first-generation agent, Peniramin is distinguished by its potential for central nervous system effects, a characteristic widely noted in pharmacological texts. This identity confirms its role as a key agent for managing acute, general allergic episodes, such as seasonal hypersensitivity.


Composition and Available Forms of Peniramin

The essential component of the medicine is Chlorphenamine maleate (or Chlorpheniramine maleate), which serves as the sole active ingredient, confirming its status as a single-component formulation. This focused composition allows for targeted H₁ receptor competitive antagonism.

Peniramin is prepared for oral intake, commonly available as a tablet or syrup, although an injectable solution is produced for use in settings where rapid parenteral administration is required. This variety of forms makes it suitable for both adult and paediatric patient groups, subject to appropriate medical guidance.


What is the General Purpose of Antihistamine Action?

The general purpose of Peniramin's action is to provide systemic relief from the acute physical manifestations of allergic conditions and generalized hypersensitivity reactions. The underlying mechanism, histamine blockade, prevents excessive histamine from activating cell receptors, thereby mitigating symptoms like itching, watery eyes, and localized swelling. These agents are a pharmacologically confirmed component of management strategies against various allergic responses.

Regulatory References

  1. Chlorpheniramine: MedlinePlus Drug Information

What side effects are possible with Peniramin?

Possible Side Effects and Safety Information: Peniramin

Peniramin, containing Chlorphenamine maleate, has an official safety profile that centers on its classification as a first-generation antihistamine, with effects most prominently documented across the Nervous System and Gastrointestinal System.


Documented Adverse Reactions

The most prominent adverse effect is Drowsiness (Somnolence), which is officially classified in regulatory documents as Very Common (ge 1/10). Other frequently listed effects, categorized as Common, include Dizziness, Headache, Fatigue, and anticholinergic effects such as Dry Mouth and Blurred Vision.

Side effects are officially grouped by System-Organ Classes, encompassing Nervous System Disorders, Gastrointestinal Disorders, and Immune System Disorders, among others.

Classification Examples of Officially Listed Effects
Very Common Drowsiness, Sedation
Common Dizziness, Dry Mouth, Nausea, Headache
Rare/Not Known Blood Dyscrasias, Anaphylactic Reactions

Safety Considerations and Restrictions

Official labeling documents address time-related patterns, noting that drowsiness may be most marked during the initial days of treatment and may diminish with continued exposure.

Serious adverse reactions, though classified as rare, include events such as Anaphylactic reactions and specific Blood Dyscrasias (e.g., Agranulocytosis). The product information also includes specific safety considerations for special populations. Older adults may be more susceptible to sedation and effects like urinary retention. Children may exhibit paradoxical excitation (e.g., restlessness) more frequently than adults.

Use is subject to caution or restriction in individuals with pre-existing conditions that could be exacerbated by anticholinergic properties, such as narrow-angle glaucoma or prostatic hypertrophy, as specified in regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Peniramin (Chlorphenamine maleate) is a serious event associated with severe toxicity and requires immediate professional medical intervention. The officially documented regulatory profile describes marked Central Nervous System (CNS) toxicity, which can present in two forms: severe CNS depression, leading to drowsiness and potentially profound coma, or CNS excitation, which includes agitation, tremor, ataxia, and convulsions. These excitation effects are particularly noted as a risk in pediatric patients. Characteristic anticholinergic signs, such as a flushed face, dilated pupils (mydriasis), and urinary retention, are also commonly documented manifestations.

The most severe outcome involves the cardiovascular system, with regulatory warnings of severe hypotension, cardiac arrhythmias, and the potential for cardiac arrest. Due to these life-threatening risks, seeking immediate medical attention or contacting emergency services immediately is mandatory in all suspected cases. Continuous hospital monitoring is required to manage potential instability. As no specific antidote is known, management must be entirely symptomatic and supportive, which may include procedural measures like gastric lavage and the administration of activated charcoal to limit further absorption. Elderly patients are noted to be more susceptible to pronounced CNS depression and anticholinergic effects.

Therapeutic Uses of Peniramin

Main Uses and Benefits of Peniramin

Peniramin is an antihistamine medication primarily used to manage symptoms associated with allergic reactions and certain upper respiratory conditions. By blocking the action of histamine—a substance produced by the body during an allergic response—it helps alleviate various localized and systemic discomforts.

Allergic Rhinitis and Hay Fever

The medication is commonly used to treat seasonal and perennial allergic rhinitis. It addresses the following symptoms:

  • Frequent sneezing
  • Itchy, runny, or blocked nose
  • Red, itchy, or watery eyes (allergic conjunctivitis)

Dermatological Conditions

Peniramin is effective in managing skin-related allergic manifestations. It is frequently utilized to provide relief from:

  • Urticaria (Hives): Reducing the appearance of red, itchy wheals on the skin.
  • Pruritus (Itching): Alleviating general itching caused by various skin irritations or allergic triggers.
  • Angioedema: Assisting in the management of localized swelling beneath the skin surface.
  • Eczema and Dermatitis: Managing the itching associated with inflammatory skin conditions.

Other Upper Respiratory Symptoms

Beyond chronic allergies, Peniramin is often used to provide temporary relief from the symptoms of the common cold or other viral infections of the upper respiratory tract, specifically focusing on reducing nasal secretions and sneezing.

Benefits of Treatment

The primary benefit of Peniramin is the stabilization of the body's allergic response. By neutralizing the effects of histamine, the medication helps to:

  • Improve daily comfort by reducing persistent irritation.
  • Minimize the physical signs of an allergic reaction.
  • Allow for better sleep and productivity by controlling symptoms that may interfere with daily activities.

Eligibility and Restrictions for Use

The eligibility for using Peniramin (Pheniramine Maleate) is defined by official regulatory documents to ensure safety and prevent adverse health outcomes.

Populations For Whom Use Is Contraindicated

Peniramin is formally contraindicated and must not be used by the following groups:

  • Patients with known hypersensitivity or allergy to pheniramine or any component in the formulation.
  • Patients currently taking or who have stopped a Monoamine Oxidase Inhibitor (MAOI) therapy within the past 14 days.
  • Individuals with narrow-angle glaucoma.
  • Patients with urinary retention or difficulty urinating due to conditions like prostatic hypertrophy.
  • Infants and neonates.

Age and Condition Restrictions

  • Pediatric Use: Use is generally not recommended in children under 6 years of age as safety and efficacy may not be established. Use in older children is determined by age-appropriate dosing.
  • Older Adults: Individuals aged 65 and over should use this medicine with caution due to a heightened risk of adverse effects, including confusion and increased sensitivity to the drug's anticholinergic properties.
  • Pre-existing Conditions: Caution is advised in patients with respiratory conditions (e.g., chronic asthma), severe hepatic or renal impairment, stenosing peptic ulcer, or certain cardiovascular conditions.

What should I know about interactions with other medicines?

Interacting Products and Constraints

The official interaction profile for Peniramin (Chlorphenamine maleate) is structured around strict regulatory constraints concerning additive effects and metabolic inhibition. Monoamine Oxidase Inhibitors (MAOIs) constitute a formally contraindicated combination in all regulatory labels. Co-administration is explicitly prohibited, and a mandatory 14-day period must elapse after stopping MAOI therapy before this medicine can be used. This strict timing restriction is imposed because MAOIs intensify the documented anticholinergic properties of Chlorphenamine, which is an acknowledged mechanism of interaction.


Additive Effects and Pharmacokinetic Risk

Pharmacodynamic potentiation is documented with several classes of co-administered products. Concomitant use with CNS depressants, including opioid analgesics, sedatives, and anxiolytics, results in documented additive central nervous system effects. Similarly, combining with other anticholinergic drugs can lead to potentiated antimuscarinic effects. A critical pharmacokinetic interaction involves the inhibition of Phenytoin's hepatic metabolism by Peniramin. This interaction reduces Phenytoin clearance, which is officially noted to carry a risk of Phenytoin toxicity. The sedative effect of Alcohol is also subject to potentiation and its concurrent use is restricted. Regulatory notes specify that elderly and pediatric populations may be more susceptible to the neurological anticholinergic effects resulting from these interactions.

Mechanism of Action

Peniramin is categorized pharmacologically as a first-generation competitive inverse agonist, primarily targeting the histamine H1 receptor. Its mechanism involves binding reversibly to the H1 receptor, thereby preventing endogenous histamine from occupying the site and initiating cellular signaling. This action occurs on H1 receptors expressed across multiple cell types, including smooth muscle and vascular endothelium.

The blockade of the H1 receptor interrupts the Gq protein-coupled signaling cascade, which normally leads to the hydrolysis of PIP2 into inositol trisphosphate ( IP3) and diacylglycerol ( DAG), followed by the release of intracellular calcium ( Ca^2+). Inhibiting this cascade modulates H1-mediated physiological effects, such as the increase in capillary permeability and the contraction of smooth muscles. Peniramin's lipophilicity also facilitates its diffusion across the blood-brain barrier, resulting in H1 receptor occupancy in the central nervous system, particularly within the CNS neurons.

Dosage and Administration Information

How Peniramin is Used: Administration Guidelines

Peniramin, containing Chlorphenamine maleate, is administered according to specific dosage and procedural instructions. This ensures correct use and adherence to established protocols.


Routes and Schedules

Administration Route Standard Adult Dose (12+ years) Maximum Daily Limit
Oral (Tablet, Syrup) 4 mg every 4 to 6 hours. 24 mg in any 24-hour period.
Parenteral (IM, SC, IV) 10 mg to 20 mg per dose. 40 mg in any 24-hour period.

Population-Specific Use Rules

Modifications are specified for certain age groups to prevent excessive exposure.

  • Older Adults: A lower daily maximum dose is generally advised, often limited to 12 mg in any 24 hours.
  • Children (6–12 years): The standard oral dose is 2 mg every 4 to 6 hours, with a maximum of 12 mg per day.
  • Children Under 6 Years: Use of standard oral tablets and syrups is not recommended.

Contextual Administration Details

All doses must maintain a minimum interval of 4 hours. For oral forms, the medicine can be taken with or without food.

When administered into a vein (intravenously), the solution must be injected slowly over a period of one minute. For liquid forms, an accurate milliliter measuring device must be used for dispensing, not household spoons.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Peniramin

Research on Peniramin (Chlorphenamine maleate) for conditions like hay fever and perennial allergic rhinitis has primarily used short-term Randomized Controlled Trials (RCTs) and systematic reviews. Studies were applied in research contexts involving fluctuating symptoms, measuring outcomes like Total Nasal Symptom Scores (TNSS) and changes in patient-reported daily functioning. Regulatory reviews report that findings describe patterns of measured symptom changes over short periods, consistent with the brief follow-up durations.

For chronic and acute urticaria (hives), the research base includes RCTs and reviews that evaluated the acute symptomatic phase. Studies explored outcomes such as the measured changes in wheal size and the measurement of pruritus (itching) levels. Scientific literature notes that the evidence quality may vary across studies, with many trials being older and follow-up often limited to the acute episode.

Peniramin was also studied for symptoms associated with the common cold through short-term, placebo-controlled clinical trials. These studies examined temporary physiological imbalance, reporting observations of modest changes in patient-reported outcomes for specific symptoms like sneezing. However, research does not determine whether the agent influences the overall duration or progression of the common cold episode.

Evidence Gaps and Limitations

While pharmacokinetic studies have explored the drug's processing in children and adolescents, evidence for other special groups like older adults or pregnant individuals remains insufficient within the main RCT literature. Across all indications, the major limitation is that follow-up durations were often limited to short periods (one to four weeks). Consequently, certainty remains low regarding sustained, long-term outcomes, and the overall research base lacks comprehensive comparative evidence against newer antihistamines.

Key Studies & References

  1. Effectiveness of Antihistamines in the Symptomatic Management of the Common Cold

Frequently Asked Questions (FAQ)

Common questions about Peniramin (FAQ)


Q: Do I need a special diet while taking Peniramin?

A: Official guidance and product information for Peniramin state that the oral form of the medicine can be taken with or without food. Regulatory information does not typically specify the need for a special diet while using this medicine. For any specific dietary concerns, consulting a healthcare professional is consistent with regulatory advice.


Q: Can Peniramin be taken with common over-the-counter pain relievers?

A: Official product information generally indicates that Peniramin may be taken with common non-prescription pain relievers such as paracetamol or ibuprofen, based on standard regulatory safety profiles. It remains important to check the labels of any over-the-counter product for specific warnings.


Q: Are there any known issues with taking Peniramin with vitamins or supplements?

A: Regulatory notes advise a cautious approach when combining Peniramin with certain vitamins or supplements. This is because some supplements may potentially increase existing side effects, such as sleepiness or dry mouth, due to additive effects. Consulting a healthcare professional regarding specific combinations is generally recommended.


Q: Can older adults generally take Peniramin, and are there specific considerations?

A: Older adults may take the medicine, but specific regulatory guidance advises that a lower daily maximum dose is generally used. Caution is noted due to the increased likelihood of neurological side effects, such as confusion, in this population. Adhering to the specific dose recommended by a prescribing professional is noted in regulatory guidance.


Q: Is Peniramin known to be safe for use during pregnancy, based on regulatory information?

A: Regulatory notes advise using the medicine during pregnancy only when there is a clear medical need. Use should generally be avoided during the third trimester of pregnancy, according to official guidance.


Q: Why is the information on Peniramin's side effects so long?

A: Regulatory documents like the Summary of Product Characteristics (SmPC) require a comprehensive listing of all adverse effects reported during clinical development and post-market use. These effects are formally grouped by the body's System Organ Classes and classified by their frequency, which results in a detailed safety profile.


Q: What happens in the body when Peniramin starts to work?

A: Peniramin's action is described by regulatory sources as competing with histamine for its H1 receptor sites in the body. By binding to these sites, the medicine prevents histamine from initiating its effects, which include localized swelling, itching, and increased capillary permeability associated with allergic reactions.


Q: What if I drink alcohol while using Peniramin?

A: Official regulatory labels include constraints regarding the concurrent use of alcohol with Peniramin. This is because alcohol may enhance the central nervous system depressant effects of the medicine, which can increase the effects of drowsiness and dizziness.


Q: How does Peniramin affect sleep patterns?

A: The medicine is classified as a sedating antihistamine. Its most prominent adverse effect is drowsiness or sedation, which is officially listed as Very Common. These sedative effects can directly influence and alter the normal sleep-wake cycle.


Q: How quickly should I expect to see an effect from Peniramin?

A: Official information indicates that Peniramin usually begins to show an effect within 30 minutes to 1 hour after taking an oral dose. The effects typically last for approximately 4 to 6 hours.


Q: If I miss a dose of Peniramin, what should I generally do?

A: Official instructions state that a missed dose should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Official instructions specify that two doses should not be taken at one time.


Q: What should I do if a side effect of Peniramin feels unusual?

A: Official labels state that if signs of a serious or unusual adverse reaction are experienced, stopping use and contacting a healthcare professional immediately is indicated. Examples of serious reactions include an irregular heartbeat, seizure, or unusual bleeding.


Q: Does Peniramin have any known effects on mental clarity or concentration?

A: Common side effects of Peniramin can include difficulty concentrating and dizziness, alongside its known effect of psychomotor impairment. Official labels advise caution when performing tasks that require concentration.


Q: Is there a maximum amount of time someone can take Peniramin?

A: Regulatory guidance for non-prescription use states that the medicine should generally not be taken continuously for longer than two weeks without consulting a doctor. This guidance is aligned with the medicine's role in providing short-term symptom relief.


Q: Does Peniramin interact with caffeine or energy drinks?

A: While not explicitly restricted in all standard labels, the potential for interaction exists when combining Peniramin with stimulants like caffeine, which can have complex effects. Official labels recommend consulting a healthcare professional regarding combinations of medications and stimulants.


Q: Is it normal to feel a change in appetite when starting Peniramin?

A: Regulatory documents sometimes list anorexia, or loss of appetite, as an adverse reaction under the Metabolism and Nutritional Disorders System Organ Class. This indicates that a change in appetite is a documented possibility when taking the medicine.


Q: Can Peniramin be used by people who have allergies to other drugs?

A: The medicine is contraindicated only for known hypersensitivity to its own active ingredient or formulation components. Individual use depends on specific cross-reactivity risks, which requires professional evaluation.


Q: Is Peniramin ever used in children?

A: Yes, Peniramin is used in children, but with specific age restrictions and reduced doses noted for ages 6 to 12. Use in children under 6 years is generally not recommended, and use in infants and neonates is formally contraindicated.


Q: Are the side effects of Peniramin permanent?

A: Official labeling notes that some common effects, such as drowsiness, may diminish with continued exposure, suggesting they are often temporary. While rare cases of long-term neurological effects have been reported in literature, they are not listed as common or expected outcomes of the medicine.


Q: Can Peniramin interact with herbal remedies, like St. John's Wort?

A: Regulatory notes advise caution when combining Peniramin with herbal remedies, particularly those that may cause side effects like sleepiness or dry mouth. This is because combining these substances may enhance the existing sedative effects of the medicine.


Q: How long does Peniramin stay in the body after the last dose?

A: Pharmacokinetic data shows that Peniramin has a wide interindividual variation in its half-life, with reported values ranging from 2 to 43 hours. The medicine is mainly eliminated from the body via the urine.


Q: Is it possible to become dependent on Peniramin?

A: Regulatory review documents noted that abuse potential assessment was not required for the single-ingredient product. The medicine is not typically classified as a controlled substance in standard regulatory categories.


Q: What evidence exists about long-term use of Peniramin?

A: Regulatory evidence indicates that the clinical study follow-up durations were often limited to short periods, typically one to four weeks. Consequently, certainty remains low regarding the sustained, long-term outcomes of using Peniramin.


Q: Are there any common misuses of Peniramin that people should know about?

A: Regulatory notes caution against taking more than the directed dose of Peniramin. Overdosage is officially associated with potentially dangerous anticholinergic and central nervous system effects, emphasizing the risk of inappropriate use.


Q: Is Peniramin a generic or a brand-name drug?

A: The active ingredient in Peniramin, Chlorpheniramine maleate, is the generic name for the compound. This compound is frequently sold under various different brand names depending on the country or jurisdiction.


Q: What is the typical duration of a single course of Peniramin treatment?

A: For symptom relief, the course of treatment is often short-term. Guidance for non-prescription use often states that continuous use is limited to two weeks unless directed otherwise by a healthcare professional.


Q: What is the difference between a common side effect and a serious one for Peniramin?

A: Official documents classify side effects primarily by how frequently they occur, such as Very Common or Common. Serious adverse reactions, such as Anaphylactic Reactions or Blood Dyscrasias, are typically classified as rare events and require immediate medical attention.


Q: Is it safe to drive a car while taking Peniramin?

A: Official regulatory labels advise against driving a car or operating machinery while taking Peniramin. This warning is due to the fact that the medicine is known to cause drowsiness, dizziness, and psychomotor impairment.

How should Peniramin be stored and disposed of?

How to Store and Dispose of Peniramin

The storage and disposal of Peniramin (Chlorphenamine maleate) must strictly follow official regulatory guidelines to ensure stability and public safety.

Required Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature (CRT), typically 20 C to 25 C (68 F to 77 F).
Protection Must be protected from light and moisture; do not freeze.
Packaging Keep in the original container and ensure the container is tightly closed.
Safety Keep out of the sight and reach of children.

Official Disposal Instructions

Unused or expired Peniramin should be disposed of through a community drug take-back program. If no program is available, the product may be mixed with an unappealing substance, sealed, and placed in household trash, according to official guidance. The medicine must not be flushed down the toilet or poured down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Peniramin found in:

A-Z Index: